<DOC>
	<DOCNO>NCT01875770</DOCNO>
	<brief_summary>This research do assess long term prognosis patient treat ranibizumab edema due retinal vein occlusion .</brief_summary>
	<brief_title>Continuing Assessment Patients Treated With ranibizUmab REtinal Vein Occlusion ( CAPTURE )</brief_title>
	<detailed_description>People treat ranibizumab edema due retinal vein occlusion part previous study Wilmer Eye Institute currently see ophthalmologist Wilmer Eye Institute follow assess long term outcome</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>All patient enrol follow three trial include study : A ) `` A Pilot , OpenLabel Study Safety , Tolerability , Bioactivity Multiple Intravitreal Injections Ranibizumab Subjects Macular Edema Secondary Vein Occlusions . `` , B ) `` Extended followup patient macular edema due bRanch rETinal vein occlusion ( BRVO ) centrAl retinal veIn occlusioN ( CRVO ) previously treat intravitreal ranibizumab ( RETAIN ) `` C ) `` RanibizumabDosE Comparison ( 0.5mg 2.0mg ) Role LAser ManagemenT REtinal Vein Occlusion A Pharmacodynamic Approach ( RELATE ) ''</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Retinal Vein Occlusion</keyword>
</DOC>